

Supplementary Table S5. Saliva anti-spike IgA and IgG levels.

	IgA	Normalized IgA	IgG	Normalized IgG
SARS-CoV-2 NI (n = 6)	0.4 (0.1-0.6) ¹	0.1 (0.0-0.1)	0.1 (0.1-0.1)	0.1 (0.0-0.1)
Vaccinated HU (n = 15)	0.6 (0.4-1.9)	0.9 (0.3-1.3)	0.5 (0.4-1.3)	0.4 (0.2-1.3)
Vaccinated HIV (n = 19)	0.5 (0.3-1.3)	0.3 (0.2-0.8)	0.4 (0.2-0.6)	0.3 (0.2-0.4)
COVID HU (n = 8)	1.2 (0.5-1.7)	0.9 (0.5-1.4)	0.2 (0.1-0.4)	0.1 (0.1-0.4)
COVID HIV (n = 13)	1.6 (0.8-2.9)	0.8 (0.3-1.2)	0.2 (0.1-0.5)	0.1 (0.0-0.2)
P value HU vs. HIV				
Vaccinated	0.554	0.073	0.225	0.036
COVID	0.310	0.500	0.790	0.310
P value Vaccinated vs. COVID				
HU	0.789	0.548	0.020	0.024
HIV	0.059	0.211	0.070	0.001

¹ Shown are medians with IQRs in brackets of spike-specific IgA and IgG levels given as antibody ratios obtained by dividing the extinction of the sample by that of the calibrator. NI: non-immune, HU: HIV-1-uninfected. A ratio of <0.8 was considered as negative, a ratio of 0.8-1.1 as borderline and ≥1.1 as positive. Significance was tested by Mann-Whitney-U tests.